Nurix Therapeutics (NASDAQ:NRIX) Receives “Overweight” Rating from Stephens

Stephens reissued their overweight rating on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report report published on Tuesday morning,Benzinga reports. The firm currently has a $31.00 price objective on the stock.

A number of other equities research analysts have also issued reports on NRIX. HC Wainwright upped their price target on Nurix Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on Nurix Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $41.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and set a $29.00 price target on shares of Nurix Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They issued an “outperform” rating and a $35.00 price objective for the company. Finally, Royal Bank of Canada reduced their target price on shares of Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 14th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $30.35.

Nurix Therapeutics Trading Up 1.4 %

Shares of NASDAQ NRIX opened at $19.96 on Tuesday. The stock has a market cap of $1.41 billion, a PE ratio of -6.86 and a beta of 2.14. Nurix Therapeutics has a 12-month low of $7.65 and a 12-month high of $29.56. The company has a 50-day moving average of $20.50 and a 200 day moving average of $22.46.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,437 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $83,519.10. Following the sale, the insider now directly owns 50,670 shares in the company, valued at $1,231,281. This represents a 6.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 9,351 shares of company stock worth $227,158 in the last three months. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NRIX. Renaissance Technologies LLC raised its position in Nurix Therapeutics by 80.7% in the 2nd quarter. Renaissance Technologies LLC now owns 324,000 shares of the company’s stock valued at $6,762,000 after purchasing an additional 144,700 shares in the last quarter. Barclays PLC raised its holdings in Nurix Therapeutics by 77.9% in the third quarter. Barclays PLC now owns 128,344 shares of the company’s stock valued at $2,884,000 after acquiring an additional 56,190 shares in the last quarter. FMR LLC lifted its stake in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company’s stock worth $13,188,000 after acquiring an additional 511,256 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Nurix Therapeutics in the 2nd quarter valued at approximately $2,271,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter valued at approximately $530,000.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.